Patients with ''difficult-to-treat'' advanced testicular cancer can require multiple therapies. We retrospectively assessed our patients with advanced germ cell tumors (GCTs) and characterized the clinical efficacy, outcomes, and factors affecting overall survival (OS).
INTRODUCTION
A dvanced metastatic germ cell tumors (GCTs) can be cured in 80% of cases. 1 Survival improvement in poor prognosis should be noted in the modern chemotherapy era. Populationbased analysis by Swedish-Norwegian group showed overall survival (OS) was 67.4% in poor prognosis. 2 However, 20% to 30% of cases of advanced GCTs require salvage chemotherapy, such as vinblastine, ifosfamide, and cisplatin (VeIP), etoposide, ifosfamide, and cisplatin (VIP), high-dose chemotherapy (HDCT), and paclitaxel, ifosfamide, and cisplatin (TIP).
Although VIP and VeIP therapy have been used as standard salvage therapy for 2 decades, no evidence of disease (NED) rate was approximately 30%. 3, 4 These results led investigators to develop other therapies. HDCT was made possible by the development of peripheral stem cell blood harvest and transfusion. Two randomized control trials (RCTs) of HDCT as first salvage therapy (second-line) failed to show that HDCT was superior to standard-dose salvage therapy. 5, 6 In addition, after failing HDCT therapy, it is very difficult to continue treatment. 7 TIP therapy as first salvage chemotherapy, introduced by Motzer in 2000, 8 results in a very good response rate (RR) in cases with specific prognostic features (eg, testis primary and first relapse after previous complete response [CR] ). Other investigators tested TIP as second-line therapy for patients with bleomycin, etoposide, and cisplatin (BEP) failure and reported relatively good results with manageable adverse events. 9 Therefore, TIP has been recognized as a standard first salvage chemotherapy, especially for the patients with favorable prognostic features.
Other salvage chemotherapies have been developed for advanced GCTs. Some of them seem to be good candidates for second-line treatment or for use after salvage chemotherapy. Gemcitabine and irinotecan in combination with cisplatin or its derivatives resulted in relatively good cure rates. 10, 11 A regimen including gemcitabine or irinotecan has mainly been used as third-line therapy or after salvage chemotherapy.
Guidelines equally recommend VeIP/VIP, TIP, and HDCT as second-line therapy. [12] [13] [14] With regard to third-line therapy, gemcitabine-containing regimens might be good candidates, but no specific regimen was mentioned recommended by the guidelines.
To our knowledge, there are no definitive data to guide the sequential treatment regimens for patients with ''difficult-totreat'' advanced testicular cancer. In addition, there are no reports that studied the entire treatment sequence and survival from induction chemotherapy to completion of treatment. Thus, the goal of this retrospective study was to assess the response and OS of sequential chemotherapy and additional modalities for patients with advanced GCT at each step of treatment, regardless of the chemotherapy regimen.
PATIENTS AND METHODS
We retrospectively assessed 253 patients having GCT with metastasis treated in our institution from June 1998 to September 2013. Patient characteristics are summarized in Table 1 . Of 253 patients, 111 patients had only first-line chemotherapy (induction group) and 142 patients had second-line-or-later chemotherapy (salvage group). The salvage group had worse initial clinical stage and International Germ Cell Cancer Collaborative Group risk criteria compared with induction group. This study was approved by the Institutional Review Board of Kyoto Prefectural University of Medicine, Kyoto, Japan, and written informed consent for each treatment was obtained from all patients.
Treatment Strategy
We treated advanced patients with GCT according to our treatment strategy, as follows: 
Response Assessment
Response assessment was carried out following every other cycle according to the Response Evaluation Criteria in Solid Tumors Criteria ver1.1. CR was defined as the disappearance of all clinically detectable disease and as STM normalization. Partial response (PR) with STM normalization (PRmÀ) was defined as !30% reduction of the tumor size and normalization of previously elevated tumor markers. PR without STM normalization was considered marker-positive PR (PRmþ). No change of visible disease (NC) was also classified as NCmÀ (NC with STM normalization) and NCmþ (NC without STM normalization). If significant STM elevation (>50%) and/or radiological progression (>25%) occurred after the beginning of treatment, the patient was classified as having PD. RR was defined as CR þ PR regardless of STM normalization. STM normalization (STMn) was defined as normal STM regardless of tumor shrinkage.
Statistical Analysis
Survival analysis was performed using the Kaplan-Meier method, and statistical difference was tested by the log-rank test. The primary endpoint was OS. Univariate and multivariate analysis were performed using JMP 10 software (SAS Institute, Inc, Cary, NC). Survival was confirmed by last visit to our institution or telephone. Table 2 shows the treatment sequence at our department with other additional procedures. Briefly, BEP or etoposide and cisplatin (EP) therapy was chosen in 234 patients as induction chemotherapy. As second-line therapy, VIP or VeIP were selected in 44 patients, and TIP or TIN was done in 59 patients. With regard to third-line therapy, the most commonly selected therapy was TIP or TIN therapy in 53 patients, and IrP or IrN were the second most commonly selected therapy (18 patients With regard to additional procedures during or after chemotherapy, 150 surgeries and 14 radiation therapies were performed during or after first-line therapy. Out of 169 RPLND carried out, 156 were integrated with first, second, and thirdline therapy.
RESULTS

Sequential Chemotherapy
Response Rate
The RRs (CR þ PR) for the second, third, and fourth-line therapies are shown in Table 3 
Overall Survival
OS stratified by required chemotherapy line is shown in Figure 1A . In this analysis, second-line meant that the final chemotherapy was second-line therapy. Thus, the number of patients who completed therapy as first line, second line, third line, fourth line, fifth line, and sixth line or after was 111, 41, 28, 23, 18, and 32 cases, respectively. Figure 1B shows OS stratified by chemotherapy line. In this analysis, ''third-line$'' represented patients who had third-line-or-after chemotherapy (eg, fourth, fifth, and sixth-line-or-after therapy). In the patients with RPLND, residual viable cancer was found in 20.5% and teratoma was found in 23.7%. The 5 and 10-year OS rate was 91.5% and 87.9%, respectively.
In the search for the best sequence from second line to third line, we could not identify a sequence that was statistical significant superior to others in any combination. The sequence of second line and third line chemotherapy with VeIP/VIP and TIP/TIN had no significant difference, compared with other combinations, such as TIP/TIN and IrP/IrN (hazard ratio; 1.02, 95% confidence interval; 0.39-3.20, P ¼ 0.97).
Statistical Analysis
Univariate and multivariate analysis are shown in Tables 4  and 5 , respectively. Univariate analysis showed significant differences in each category of the International Germ Cell Consensus Classification, each clinical stage, doing RPLND or not, doing extra-RPLN resection or not, with or without radiation, and achieving STM normalization or not. Multivariate analysis showed significant differences in each clinical stage, doing RPLND or not, doing extra-RPLN resection or not, with or without radiation and achieving STM normalization or not. BEP ¼ bleomycin, etoposide, and cisplatin, EBRT ¼ external beam radiotherapy, ExRPLN ¼ extraretroperitoneal lymph node, HDCT ¼ high-dose chemotherapy, IrN ¼ irinotecan and nedaplatin, IrP ¼ irinotecan and cisplatin, PVB ¼ cisplatin, vinblastine, and bleomycin, RFA ¼ radiofrequency ablation, RPLND ¼ retroperitoneal lymph node dissection, SRT ¼ stereotactic radiotherapy, TGN ¼ paclitaxel, gemcitabine, and nedaplatin, TGP ¼ paclitaxel, gemcitabine, and cisplatin, TIN ¼ paclitaxel, ifosfamide, and nedaplatin, TIP ¼ paclitaxel, ifosfamide, and cisplatin, VeIP ¼ vinblastine, ifosfamide, and cisplatin, VIP ¼ etoposide, ifosfamide, and cisplatin. The number in the ''fifth line$'' column indicates the number of therapy that was performed as fifth-line therapy.
DISCUSSION
BEP therapy is widely used as first-line therapy for advanced testicular cancer. On the contrary, only 2 phase III trials of HDCT in the second-line setting have been performed, 4, 5 and there are no RCTs of conventional-dose salvage chemotherapy. Therefore, guidelines do not recommend salvage chemotherapy. [12] [13] [14] Our institutional strategy for advanced GCT was BEP/EP as induction chemotherapy, TIP/TIN (substitute nedaplatin for cisplatin) as second-line, IrP/IrN as third-line, and TGP/TGN as fourth-line therapy. Therefore, TIP/TIN was the most common regimen selected as second line. The second most common choice for second-line therapy was VIP/VeIP. This is compatible with guidelines' recommendation. In the third-line or later setting, paclitaxel, irinotecan, or gemcitabine were selected ( Table 3) .
As shown in Table 6 , after introducing ifosfamide, VIP or VeIP has been used as second-line therapy. Although its efficacy was relatively good, long NED could be achieved in about 30%, which is suboptimal. 3, 4 This led investigators to introduce HDCT with stem cell transfusion. Two RCTs did not show superiority of HDCT to conventional dose chemotherapy (CDCT). 5, 6 These unsatisfactory results led to the development of new regimens with paclitaxel, 8, 9, 15 gemcitabine, 11,16-18 and irinotecan. 10, 19, 20 Most reports that have investigated chemotherapy regimens as second or third-line therapy showed relatively good results (OS of 20%-50%). Paclitaxel-containing therapy resulted in good survival rates when used in the second and third-line setting. From these results, the efficacy of HDCT was thought to be very limited, and paclitaxel-containing chemotherapy was promising as second or third-line therapy. In fact, our data showed that TIP/TIN resulted in a good response and in tumor marker normalization. For thirdline therapy, our results showed an OS rate of 62.2%, which was better than the OS (20%) seen in previous studies. 11, 15, 16, 19 In addition, sequential chemotherapy, even after fourth line, produced a good RR and a good OS rate.
Recently, Necchi et al 21 used modified VIP as second-line therapy in a large cohort. This report showed that 2-year progression-free survival (PFS) and 5-year OS was 34.3% and 42.1%, respectively. Another large retrospective study by Lorch et al 22 showed better second-line outcomes with HDCT than with CDCT. PFS in all subgroups was better after HDCT than CDCT and OS was better than CDCT in all except 1 (low risk).
HDCT seemed to be superior to CDCT. However, since CDCT and HDCT regimen were varied and selection bias must exist in a retrospective nature, definitive conclusion could not be obtained. Therefore, superiority of CDCT or HDCT should be reevaluated in a prospective RCT for patients with poor prognostic features, such as TIGER (Randomized Phase III Trial of Initial Salvage Chemotherapy for Patients with Germ Cell Tumors) study. 23 Despite the absence of evidence from RCTs, TIP is effective first salvage chemotherapy. Furthermore, treatment options are more complicated in the third-line or later setting. Our sequential treatment strategy was comparable or better in terms of OS compared with reported literatures in each salvage chemotherapy line. These observations highlight the importance of sequential continuous chemotherapy integrated with residual mass resection. With regard to the best sequence up to third-line chemotherapy, the combination of TIP (microtubule polymerization inhibitor) as second line and gemcitabine (antimetabolite) as third line seems to be the most common sequence in the literature. Irinotecan (topoisomerase I inhibitor) was also a good candidate as second-line-or-later chemotherapy. However, we could not identify the best sequence in this series. Further investigation using anticancer agents with different mechanisms is required. BEP ¼ bleomycin, etoposide, and cisplatin, HDCT ¼ high-dose chemotherapy, IrN ¼ irinotecan and nedaplatin, IrP ¼ irinotecan and cisplatin, PVB ¼ cisplatin, vinblastine, and bleomycin, RFA ¼ radiofrequency ablation, RPLND ¼ retroperitoneal lymph node dissection, RR ¼ response rate, SRT ¼ stereotactic radiotherapy, STMn ¼ serum tumor marker normalization, TGN ¼ paclitaxel, gemcitabine, and nedaplatin, TGP ¼ paclitaxel, gemcitabine, and cisplatin, TIN ¼ paclitaxel, ifosfamide, and nedaplatin, TIP ¼ paclitaxel, ifosfamide, and cisplatin, VeIP ¼ vinblastine, ifosfamide, and cisplatin, VIP ¼ etoposide, ifosfamide, and cisplatin.
Residual mass resection is an important and essential part of GCT treatment. [12] [13] [14] The rate of persistent viable cancer and teratoma are 10% and 40%, respectively, in the modern chemotherapy era. Disease-specific survival rate is reported to be 75% in the literature. [24] [25] [26] [27] Our data involving patients with complicated background showed that viable cancer was found in 20.5% and that teratoma was found in 23.7%. The 5 and 10-year OS rate was 91.5% and 87.9%, respectively. These results are comparable to those from the previous reports. [24] [25] [26] [27] The results of univariate and multivariate analysis suggest that it is very important to continue chemotherapy sequentially until STM normalization and resect residual mass, including RPLN and extra-RPLN, after finishing chemotherapy. Guidelines emphasize this point. [12] [13] [14] This study has several limitations. First, this was a retrospective study of unselected patients. Second, since multiple centers contributed and only a small number of patients started induction chemotherapy at our institution, the treatment strategy was inconsistent, and patient backgrounds were heterogeneous in each treatment. Third, prognostic factors were unadjusted when comparing RRs. This is the first report of sequential continuous treatment that described the response and survival in each treatment line in the real clinical world. We believe these data show the importance of sequential treatment for advanced GCTs, despite the various study limitations.
In conclusion, this is the first report of multimodal and chemotherapeutic sequences for patients with advanced GCT. Sequential treatment for advanced GCTs, especially ''difficultto-treat'' GCTs, is very important to improve outcomes. Very high cure rates were achieved in patients who completed chemotherapy up to third-line therapies. In addition, even in heavily treated patients who had fifth or sixth-line therapy, continuous treatment might save their lives if accompanied by additional modalities. More systematic trials that include thirdline or fourth-line treatment are needed. 
